ALDX (Aldeyra Therapeutics) 5-Year RORE % : -16.18% (As of Mar. 2026)


ALDX Aldeyra Therapeutics Inc ALDX
29 GF Score
Price $2.13
! 2 Warning Signs
View Full Analysis

What is Aldeyra Therapeutics 5-Year RORE %?

Aldeyra Therapeutics ALDX +3.90% 29 5-Year RORE % is -16.18 as of Mar. 2026. GuruFocus rates ALDX with a GF Score™ of 29/100. The stock has 2 warning signs investors should review. Among 1,138 Biotechnology companies, Aldeyra Therapeutics ranks worse than 57.64% on this metric.

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Aldeyra Therapeutics's 5-Year RORE % for the quarter that ended in Mar. 2026 was -16.18%.

The industry rank for Aldeyra Therapeutics's 5-Year RORE % or its related term are showing as below:

ALDX's 5-Year RORE % is ranked worse than
57.64% of 1138 companies
in the Biotechnology industry
Industry Median: -10.67 vs ALDX: -16.18

Aldeyra Therapeutics  (NAS:ALDX) 5-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 5-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Aldeyra Therapeutics 5-Year RORE % Related Terms


Aldeyra Therapeutics 5-Year RORE % Historical Data

* Premium members only.

The historical data trend for Aldeyra Therapeutics's 5-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aldeyra Therapeutics 5-Year RORE % Chart

Aldeyra Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
5-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.33 -10.16 -25.98 -3.73 -11.94

Aldeyra Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
5-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.29 -4.60 -8.28 -11.94 -16.18

ALDX vs ONCY, VRCA, CUE: 5-Year RORE % Comparison

For the Biotechnology subindustry, Aldeyra Therapeutics's 5-Year RORE %, along with its competitors' market caps and 5-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aldeyra Therapeutics 5-Year RORE % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aldeyra Therapeutics's 5-Year RORE % distribution charts can be found below:

* The bar in red indicates where Aldeyra Therapeutics's 5-Year RORE % falls into.


ALDX
29GF Score
Aldeyra Therapeutics Inc ALDX
5-Year RORE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aldeyra Therapeutics 5-Year RORE % Calculation

Aldeyra Therapeutics's 5-Year RORE % for the quarter that ended in Mar. 2026 is calculated as:

5-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 5-year -Cumulative Dividends per Share for 5-year )
=( -0.45--1.11 )/( -4.08-0 )
=0.66/-4.08
=-16.18 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 5-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 5-year before.

Frequently Asked Questions Learn more about 5-Year RORE % →
What does a 5-Year RORE % of -16.18 mean?
Aldeyra Therapeutics (ALDX) has a 5-Year RORE % of -16.18 as of Mar. 2026. 5-Year RORE % shows how much a company earns by reinvesting its retained earnings in 5-year. View historical data on Aldeyra Therapeutics and its competitors. According to the industry distribution chart, Aldeyra Therapeutics ranks #656 out of 1138 companies in the Biotechnology industry, placing it in the top 57.6%.
Is Aldeyra Therapeutics' 5-Year RORE % too high?
Aldeyra Therapeutics' current 5-Year RORE % is -16.18. Based on the distribution chart, Aldeyra Therapeutics ranks #656 out of 1138 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Aldeyra Therapeutics has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Aldeyra Therapeutics' 5-Year RORE % compare to ONCY and VRCA?
According to the Biotechnology industry distribution chart, Aldeyra Therapeutics ranks #656 out of 1138 companies for 5-Year RORE %. This places Aldeyra Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year RORE % for a Biotechnology company?
A good 5-Year RORE % depends on the Biotechnology industry context. However, 5-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year RORE % mean?
A high 5-Year RORE % can signal that a stock is expensive relative to its fundamentals. 5-Year RORE % shows how much a company earns by reinvesting its retained earnings in 5-year. View historical data on Aldeyra Therapeutics and its competitors. Aldeyra Therapeutics's current 5-Year RORE % is -16.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aldeyra Therapeutics stock overvalued right now?
Aldeyra Therapeutics (ALDX) has a current 5-Year RORE % of -16.18. The current 5-Year RORE % is -16.18. Aldeyra Therapeutics' overall GF Score™ is 29/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year RORE % calculated?
5-Year RORE % is calculated from a company's financial statements. For Aldeyra Therapeutics (ALDX), the current 5-Year RORE % is -16.18 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aldeyra Therapeutics Business Description

Other Exchanges 137:Germany
Address 131 Hartwell Avenue, Suite 320, Lexington, MA, USA, 02421
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
29GF Score

Get the complete analysis for ALDX

5-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.13
Price